FIELD: biotechnology.
SUBSTANCE: disclosed are versions of an antibody which specifically binds to GARP. Also disclosed is a polynucleotide coding said antibody, comprising said polynucleotide expression vector and a host cell, a method of producing said antibody. Invention also relates to a pharmaceutical composition for use in anticancer therapy and a method of treating a tumor using said antibody.
EFFECT: invention provides producing an anti-GARP antibody which exhibits inhibitory activity on Treg function, exhibits ADCC activity and can be used as a therapeutic anticancer agent.
37 cl, 45 dwg, 2 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| ANTI-GARP-TGF-β-ANTIBODIES | 2018 |
|
RU2767784C2 |
| ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
| ANTI-ORAI1 ANTIBODY | 2015 |
|
RU2724742C2 |
| ANTIBODY AGAINST GPR20 AND ANTIBODY AGAINST GPR20-DRUG CONJUGATES | 2018 |
|
RU2772804C2 |
| PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 | 2019 |
|
RU2783762C2 |
| ANTIBODY AGAINST CD147 | 2018 |
|
RU2785293C2 |
| HUMAN TLR7 ANTIBODY | 2019 |
|
RU2808123C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
